卫光生物牵头出资4000万元打造细胞与基因治疗平台

Group 1 - The core announcement involves Weigao Bio's plan to jointly establish Shenzhen Xihe Life Technology Co., Ltd. with three other companies, focusing on creating a public service platform for the cell and gene therapy market in Shenzhen [1][3] - The initial registered capital of Xihe Life Technology is set at 100 million RMB, with Weigao Bio being the largest shareholder, contributing 40 million RMB for a 40% stake [1] - The platform aims to empower the commercialization and standardization of the CGT (cell and gene therapy) industry, addressing challenges such as high production costs, lack of unified standards, and insufficient market experience [3] Group 2 - The initiative will focus on a full industry chain layout from plasmids to viral vectors and cell drugs, aiming to establish a production and testing system that meets GMP standards [3] - The goal is to accelerate technology transfer and create a sustainable business ecosystem, positioning the platform as a national model for innovation in CGT public services [3]